Comparable ability of GS‐0189 combined with cetuximab to potentiate phagocytosis by PBMC‐derived macrophages from SIRPαV1/V1‐ and SIRPαV2/V2‐expressing donors was previously demonstrated using HT‐29 cells, the epidermal growth factor receptor–expressing human tumor cell line, as the target cell [23]. Here, EGFR is linked to neoplasm.